[1]
|
Aniwan, S., Santiago, P., Loftus, E.V. and Park, S.H. (2022) The Epidemiology of Inflammatory Bowel Disease in Asia and Asian Immigrants to Western Countries. United European Gastroenterology Journal, 10, 1063-1076. https://doi.org/10.1002/ueg2.12350
|
[2]
|
Park, J. and Cheon, J.H. (2021) Incidence and Prevalence of Inflammatory Bowel Disease across Asia. Yonsei Medical Journal, 62, 99-108. https://doi.org/10.3349/ymj.2021.62.2.99
|
[3]
|
Wils, P., Danese, S. and Peyrin-Biroulet, L. (2023) Promising Phase II Biologics for Future Crohn’s Disease Therapy. Expert Opinion on Investigational Drugs, 32, 495-507. https://doi.org/10.1080/13543784.2023.2219386
|
[4]
|
Pillay, L. and Subramanian, S. (2024) The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae025
|
[5]
|
Keam, S.J. (2023) Mirikizumab: First Approval. Drugs, 83, 1045-1052. https://doi.org/10.1007/s40265-023-01909-1
|
[6]
|
Sakuraba, A., Sato, T., Kamada, N., Kitazume, M., Sugita, A. and Hibi, T. (2009) Th1/th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn’s Disease. Gastroenterology, 137, 1736-1745. https://doi.org/10.1053/j.gastro.2009.07.049
|
[7]
|
Fanizza, J., D’Amico, F., Lusetti, F., Fasulo, E., Allocca, M., Furfaro, F., et al. (2023) The Role of IL-23 Inhibitors in Crohn’s Disease. Journal of Clinical Medicine, 13, Article 224. https://doi.org/10.3390/jcm13010224
|
[8]
|
Geremia, A. and Jewell, D.P. (2012) The IL-23/IL-17 Pathway in Inflammatory Bowel Disease. Expert Review of Gastroenterology & Hepatology, 6, 223-237. https://doi.org/10.1586/egh.11.107
|
[9]
|
Wallace, K.L. (2014) Immunopathology of Inflammatory Bowel Disease. World Journal of Gastroenterology, 20, 6-21. https://doi.org/10.3748/wjg.v20.i1.6
|
[10]
|
Zhang, S., Zhong, R., Tang, S., Chen, L. and Zhang, H. (2024) Metabolic Regulation of the Th17/Treg Balance in Inflammatory Bowel Disease. Pharmacological Research, 203, Article 107184. https://doi.org/10.1016/j.phrs.2024.107184
|
[11]
|
Chen, L., Ruan, G., Cheng, Y., Yi, A., Chen, D. and Wei, Y. (2023) The Role of Th17 Cells in Inflammatory Bowel Disease and the Research Progress. Frontiers in Immunology, 13, Article 1055914. https://doi.org/10.3389/fimmu.2022.1055914
|
[12]
|
Hanzel, J., Ma, C. and Jairath, V. (2023) Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis. Immunotherapy, 15, 1199-1208. https://doi.org/10.2217/imt-2023-0012
|
[13]
|
Steere, B., Beidler, C., Martin, A., Bright, S., Kikly, K. and Benschop, R.J. (2023) Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the P19 Subunit of Il-23. Journal of Pharmacology and Experimental Therapeutics, 387, 180-187. https://doi.org/10.1124/jpet.122.001512
|
[14]
|
Sandborn, W.J., Ferrante, M., Bhandari, B.R., Berliba, E., Feagan, B.G., Hibi, T., et al. (2020) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Ulcerative Colitis. Gastroenterology, 158, 537-549.E10. https://doi.org/10.1053/j.gastro.2019.08.043
|
[15]
|
D’Haens, G., Dubinsky, M., Kobayashi, T., Irving, P.M., Howaldt, S., Pokrotnieks, J., et al. (2023) Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 388, 2444-2455. https://doi.org/10.1056/nejmoa2207940
|
[16]
|
Sands, B.E., D’Haens, G., Clemow, D.B., et al. (2024) Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results from the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases.
|
[17]
|
Sands, B.E., Peyrin-Biroulet, L., Kierkus, J., Higgins, P.D.R., Fischer, M., Jairath, V., et al. (2022) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn’s Disease. Gastroenterology, 162, 495-508. https://doi.org/10.1053/j.gastro.2021.10.050
|
[18]
|
Sandborn, W.J., Ferrante, M., Bhandari, B.R., et al. (2022) Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 20, 105-115.e14.
|